The clinical research team at Scripps Whittier Diabetes Institute is conducting a new study for people with type 2 diabetes on long acting insulin. This study will evaluate whether the use of a smartphone app that helps with insulin management can improve blood glucose control.
TO BE ELIGIBLE*, YOU MUST:
- Be 18 years of age or older
- Be diagnosed with type 2 diabetes mellitus
- Be currently on long acting insulin (i.e. Lantus, Tresiba, Levemir, Toujeo, Basaglar) or about to start a long acting insulin
- Not be on mealtime insulin or steroids
- Have HbA1c between 7.5-12.5%
- Have a smart mobile device (iPhone, Android phone, etc.) with data or Wi-Fi capability
- Actively use a blood glucose meter
- Be able to speak, read, and write in English
- Three or four in-person study visits (at a Scripps Clinic) over a 16-week period; participants will be compensated for each completed visit ($300 total for all visits)
- Tresiba insulin, lancets, strips supply for 16 weeks period (at no cost to the patient)
- Lab tests (at no cost to the patient) for HbA1c
- Check your fasting blood sugar daily
- Bringing in your blood glucose meter to upload at the study visits
- Complete questionnaires on feelings and attitudes towards diabetes at two study visits
This is a voluntary study and you have the option of withdrawing at any time. Your information will be kept confidential.
*Additional inclusion/exclusion criteria may apply.
To find out more information or if you have any questions, please feel free to contact:
Alessandra Kitishian, RD, CDE, MBA, MPM, Clinical Research Project Manager
Click below for a pdf of the flyer.